Top Page
WuXi XDC Cayman, Inc.
(2268)
WuXi XDC Cayman, Inc. (2268) vs. iShares MSCI Hong Kong ETF (EWH)
WuXi XDC Cayman, Inc. Business Overview & Revenue Model
WuXi XDC Cayman, Inc. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.09B | 4.05B | 2.12B | 990.42M | 311.13M | 96.35M |
| Gross Profit | 1.68B | 1.24B | 559.56M | 261.08M | 113.49M | 8.08M |
| EBITDA | 1.42B | 1.33B | 420.28M | 151.75M | 77.37M | 7.10M |
| Net Income | 1.33B | 1.07B | 283.54M | 155.73M | 54.93M | 26.30M |
Balance Sheet | ||||||
| Total Assets | 10.62B | 9.12B | 6.74B | 2.50B | 879.75M | 408.47M |
| Cash, Cash Equivalents and Short-Term Investments | 4.54B | 3.97B | 4.05B | 734.97M | 26.32M | 28.39M |
| Total Debt | 1.04B | 496.43M | 2.84M | 77.18M | 24.59M | 0.00 |
| Total Liabilities | 3.18B | 2.48B | 1.28B | 1.02B | 858.87M | 32.79M |
| Stockholders Equity | 7.44B | 6.64B | 5.45B | 1.48B | 20.88M | 375.68M |
Cash Flow | ||||||
| Free Cash Flow | -99.81M | -787.95M | -206.51M | 50.43M | 7.23M | -32.03M |
| Operating Cash Flow | 1.54B | 717.22M | 332.85M | 251.82M | 59.14M | 20.85M |
| Investing Cash Flow | -5.00B | -3.33B | -91.23M | -1.28B | -51.59M | -52.42M |
| Financing Cash Flow | 967.91M | 475.36M | 3.52B | 1.33B | 22.34M | 69.12M |
WuXi XDC Cayman, Inc. Technical Analysis
WuXi XDC Cayman, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$88.15B | 58.95 | 19.62% | ― | ― | ― | |
71 Outperform | HK$297.96B | 17.92 | 25.65% | 1.73% | 11.55% | 64.46% | |
61 Neutral | €48.92B | 56.34 | 2.72% | 0.82% | -3.81% | -34.76% | |
56 Neutral | HK$26.01B | 59.92 | 2.74% | 0.15% | -21.76% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
WuXi XDC Cayman, Inc. Corporate Events
WuXi XDC Cayman Inc. has announced an extraordinary general meeting to be held on December 12, 2025, to discuss and approve several resolutions related to service agreements with WuXi Biologics and WuXi AppTec. These resolutions include revised maximum service fees and new master services agreements, which are expected to impact the company’s operational framework and strategic partnerships.
WuXi XDC Cayman Inc., a company incorporated in the Cayman Islands, has announced revisions to its annual caps for relevant Continuing Connected Transactions (CCT) agreements, the renewal of existing CCT agreements, and the introduction of new CCT agreements. The company has provided supplemental information regarding its pricing policies for the Conjugation Discovery Services Agreement, ensuring that service fees are determined through arm’s length negotiation and are in line with market rates. This move is intended to ensure that transactions are conducted on normal commercial terms and are in the interests of the company and its shareholders.
WuXi XDC Cayman Inc. has announced the closure of its register of members in anticipation of an extraordinary general meeting (EGM) scheduled for December 12, 2025. This meeting will allow independent shareholders to vote on the revision and renewal of key service agreements related to antibodies and payload-linkers, which are significant for the company’s ongoing operations and strategic positioning in the biotechnology sector.
WuXi XDC Cayman Inc. has completed a connected transaction involving the subscription of new shares under a specific mandate. On October 22, 2025, WuXi Biologics successfully subscribed to 24,134,000 new shares at a price of HK$58.85 per share, resulting in net proceeds of approximately HK$1,414.47 million. This transaction has increased WuXi Biologics’ shareholding in the company from 49.75% to 50.72%, slightly altering the company’s shareholding structure.
WuXi XDC Cayman Inc. announced the successful passing of a resolution at their Extraordinary General Meeting held on October 9, 2025. The resolution involved a subscription agreement with WuXi Biologic (Cayman) Inc. for the issuance of 24,134,000 new shares at HK$58.85 per share, which was unanimously approved by the shareholders. This agreement is expected to strengthen WuXi XDC’s capital base and enhance its strategic positioning in the market.
WuXi XDC Cayman, Inc. has announced revisions to its annual caps for existing connected transactions (CCTs) and plans to renew these agreements for an additional three years, reflecting its strong financial performance and anticipated demand. The company also proposes new CCTs to maximize its manufacturing capacity, subject to regulatory requirements, indicating a strategic move to sustain its growth trajectory and strengthen its market position.
WuXi XDC Cayman Inc. has announced an extraordinary general meeting to approve a subscription agreement with WuXi Biologic (Cayman) Inc. The agreement involves issuing 24,134,000 new shares at HK$58.85 each, which is expected to enhance the company’s capital structure and support its growth initiatives.
WuXi XDC Cayman Inc. has announced the closure of its register of members in anticipation of an Extraordinary General Meeting (EGM) scheduled for October 9, 2025. This meeting will allow independent shareholders to consider and potentially approve a Subscription Agreement and related transactions. The register will be closed from October 6 to October 9, 2025, during which no share transfers will be registered, ensuring that only eligible shareholders can attend and vote at the EGM.